Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Musta vaikutus: psykososiaalisen stressin vähentämisen taustalla olevat mekanismit sydän- ja verisuoniterveyteen liittyvissä toimenpiteissä

maanantai 2. marraskuuta 2026 päivittänyt: Joshua Joseph, MD, Ohio State University

Lower attainment of cardiovascular health (CVH), indicated by the American Heart Association's Life's Simple 7 (LS7; physical activity, diet, cholesterol, blood pressure, body mass index, smoking, glycemia) and Life's Essential 8 (LE8; LS7+sleep) metrics, is a major contributor to Black men having the shortest life-expectancy of any non-indigenous race/sex group. Unfortunately, a paucity of literature exists on interventions aimed at improving CVH among Black men. The team of clinician scientists and community partners co-developed a community-based lifestyle intervention titled Black Impact: a 24-week intervention for Black men with less-than-ideal CVH (<4 LS7 metrics in the ideal range) with 45 minutes of weekly physical activity, 45 minutes of weekly health education, and engagement with a health coach, group fitness trainer, and community health worker. Single-arm pilot testing of the intervention (n=74) revealed high feasibility, acceptability, and retention and a 0.93 (95% confidence interval: 0.40, 1.46, p<0.001) point increase in LS7 score at 24 weeks. Secondary outcomes included improvements in psychosocial stress (i.e., perceived stress, depressive symptoms), patient activation, and social needs. Thus, robustly powered clinical trials are needed to determine the efficacy of Black Impact and to evaluate the underlying interpersonal and molecular pathways by which Black Impact improves psychosocial stress and CVH. Thus, the investigators propose a randomized, wait-list controlled trial of Black Impact. This novel, community-based intervention to provide a scalable model to improve CVH and psychosocial stress at the population level and evaluate the biological underpinnings by which the intervention mitigates cardiovascular disease risk. The proposed study aligns with American Heart Association's commitment to addressing CVH equity through innovative, multi-modal solutions.

Tutkimuksen yleiskatsaus

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

348

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

    • Ohio
      • Columbus, Ohio, Yhdysvallat, 43202
        • The Ohio State University

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Uros

Kuvaus

Inclusion Criteria:

  • The inclusion criteria are: 1) Black men (self-report); 2) adult age 18 years or older; 3) Life's Essential 8 total average score < 80; 4) English speaking; and 5) lives in Metropolitan Columbus, Ohio.

Exclusion Criteria:

  • healthcare provider-imposed limitations on physical activity.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Ennaltaehkäisy
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Yksittäinen

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Black Impact Intervention

Black Impact Intervention

The Black Impact intervention is an academic-community-government partnership adapted from the Diabetes Prevention Program and American Heart Association Check, Change, Control programs based on stakeholder feedback and to afford incorporation of additional evidence-based strategies for influencing target outcomes. The intervention is a 24-week community-based lifestyle intervention to improve cardiovascular health among Black men. Each participant will be assigned to a group with >5 participants based on participant proximity to a central community meeting location. Each team will be guided weekly by a health coach who delivers content and coaching around the lifestyle intervention modeled on the diabetes prevention program and check, change, control blood pressure program, a community health worker who helps to address social needs and connects participants to primary care services, and a trainer who leads physical activity. Teams meet for 90 minutes per week.

Ei väliintuloa: Black Impact Waitlist Control

Usual Care

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Cardiovascular Health
Aikaikkuna: 24 weeks

The primary outcome for the randomized controlled trial is change in cardiovascular health at 24-week follow-up, which will be calculated using between-subject differences rather than within-subject differences, using a linear mixed-effects to evaluate changes from baseline in Life's Essential 8 score (range 0-100, higher scores are better). Study wave will be a covariate in the models. The model will contain data from baseline (0 weeks), during-intervention (12 weeks), and post-intervention (24-weeks). These models will assess differences between waitlist control and intervention participants using an interaction between time and treatment indicator. Residual plots will examine model assumptions and model fit, with transformation of the outcomes (e.g. log, square-root, Box-Cox) used as needed to satisfy modelling assumptions (e.g. normality, constant variance) and achieve appropriate model fit.

24 weeks

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in Perceived Stress
Aikaikkuna: 24 weeks

Change in psychosocial stress (perceived stress) will be examined using changes in the perceived stress scale via linear mixed models with subject level random effects to account for longitudinal measures on each subject, with treatment by time interactions testing differences in changes over time across study arms. Model fitting strategy will check model specification and fit by examining concordance with distributional assumptions.

24 weeks
Change in Life's Essential 8 Blood Pressure
Aikaikkuna: 24 weeks

Change in Life's Essential 8 Blood Pressure (range 0-100, higher is better) will be measured via an automated sphygmomanometer and examined using linear mixed models with subject level random effects will account for longitudinal measures on each subject, with treatment by time interactions testing differences in changes over time across study arms. Model fitting strategy will check model specification and fit by examining concordance with distributional assumptions.

24 weeks
Change in Life's Essential 8 Blood Lipids
Aikaikkuna: 24 weeks

Change in Life's Essential 8 Blood Lipids via Non-HDL Cholesterol (range 0-100, higher is better) will be measured via a blood sample and examined using linear mixed models with subject level random effects will account for longitudinal measures on each subject, with treatment by time interactions testing differences in changes over time across study arms. Model fitting strategy will check model specification and fit by examining concordance with distributional assumptions.

24 weeks
Change in Life's Essential 8 Blood Glucose
Aikaikkuna: 24 weeks

Change in Life's Essential 8 Blood Glucose via hemoglobin A1c (range 0-100, higher is better) will be measured via a blood sample and examined using linear mixed models with subject level random effects will account for longitudinal measures on each subject, with treatment by time interactions testing differences in changes over time across study arms. Model fitting strategy will check model specification and fit by examining concordance with distributional assumptions.

24 weeks
Change in Life's Essential 8 Body Mass Index
Aikaikkuna: 24 weeks

Change in Life's Essential 8 Body Mass Index via body mass index measurement from height (meters) and weight (kilograms), calculated as kilograms per meter squared (range 0-100, higher is better) and examined using linear mixed models with subject level random effects will account for longitudinal measures on each subject, with treatment by time interactions testing differences in changes over time across study arms. Model fitting strategy will check model specification and fit by examining concordance with distributional assumptions.

24 weeks
Change in Life's Essential 8 Diet (subjective)
Aikaikkuna: 24 weeks

Change in Life's Essential 8 Diet (subjective) measured via the 16-item Mediterranean Eating Pattern for Americans (range 0-100, higher is better) and examined using linear mixed models with subject level random effects will account for longitudinal measures on each subject, with treatment by time interactions testing differences in changes over time across study arms. Model fitting strategy will check model specification and fit by examining concordance with distributional assumptions.

24 weeks
Change in Life's Essential 8 Diet (objective)
Aikaikkuna: 24 weeks

Change in Life's Essential 8 Diet (objective) measured via dermal carotenoids using the Veggiemeter (range 0-100, higher is better) and examined using linear mixed models with subject level random effects will account for longitudinal measures on each subject, with treatment by time interactions testing differences in changes over time across study arms. Model fitting strategy will check model specification and fit by examining concordance with distributional assumptions.

24 weeks
Change in Life's Essential 8 Physical Activity (subjective)
Aikaikkuna: 24 weeks

Change in Life's Essential 8 Physical activity (subjective) measured via self-reported minutes of moderate or vigorous PA per week (range 0-100, higher is better) and examined using linear mixed models with subject level random effects will account for longitudinal measures on each subject, with treatment by time interactions testing differences in changes over time across study arms. Model fitting strategy will check model specification and fit by examining concordance with distributional assumptions.

24 weeks
Change in Life's Essential 8 Physical Activity (objective)
Aikaikkuna: 24 weeks

Change in Life's Essential 8 Physical activity (objective) measured via 1 week of accelerometry using an actigraph watch (range 0-100, higher is better) and examined using linear mixed models with subject level random effects will account for longitudinal measures on each subject, with treatment by time interactions testing differences in changes over time across study arms. Model fitting strategy will check model specification and fit by examining concordance with distributional assumptions.

24 weeks
Change in Life's Essential 8 Nicotine Exposure
Aikaikkuna: 24 weeks

Change in Life's Essential 8 nicotine exposure measured via self-reported use of cigarettes or inhaled nicotine delivery system (range 0-100, higher is better) and examined using linear mixed models with subject level random effects will account for longitudinal measures on each subject, with treatment by time interactions testing differences in changes over time across study arms. Model fitting strategy will check model specification and fit by examining concordance with distributional assumptions.

24 weeks
Change in Life's Essential 8 Sleep Health
Aikaikkuna: 24 weeks

Change in Life's Essential 8 sleep health measured via self-reported average hours of sleep per night (range 0-100, higher is better) and examined using linear mixed models with subject level random effects will account for longitudinal measures on each subject, with treatment by time interactions testing differences in changes over time across study arms. Model fitting strategy will check model specification and fit by examining concordance with distributional assumptions.

24 weeks
Change in Central Aortic Pressure
Aikaikkuna: 24 weeks

Change in central aortic pressure (mmHg) measured via the Sphygmocor XCEL device will be examined using linear mixed models with subject level random effects will account for longitudinal measures on each subject, with treatment by time interactions testing differences in changes over time across study arms. Model fitting strategy will check model specification and fit by examining concordance with distributional assumptions.

24 weeks
Change in carotid-femoral pulse wave velocity
Aikaikkuna: 24 weeks

Change in carotid-femoral pulse wave velocity (meters/second) measured via the Sphygmocor XCEL device will be examined using linear mixed models with subject level random effects will account for longitudinal measures on each subject, with treatment by time interactions testing differences in changes over time across study arms. Model fitting strategy will check model specification and fit by examining concordance with distributional assumptions.

24 weeks
Change in patient activation
Aikaikkuna: 24 weeks

Convergent parallel mixed methods will be used to integrate the quantitative and qualitative data on patient activation measured via the Patient Activation Measure at 12 and 24 weeks using the analytic framework described in the primary outcome. Qualitative analysis will involve in-depth immersion in the transcripts and audio and the iterative creation and synthesis of analytical memos and codes to organize data toward thematic insights. The investigators will use a deductive-dominant approach wherein a subset of central codes are determined a priori to focus the analysis, with inductive emergence of additional codes during analysis. The investigators will use Nvivo to facilitate coding and analysis. Mechanistic understanding of observed cardiovascular health will ultimately be enhanced via narrative based integration of qualitative and quantitative data.

24 weeks
Change in Social Needs
Aikaikkuna: 24 weeks

Convergent parallel mixed methods will be used to integrate the quantitative and qualitative data to capture the effect of the intervention on social needs. The quantitative analysis will use the data from the Centers for Medicare and Medicaid Services Accountable Health Communities Health-Related Social Needs Screening Tool at 12 and 24 weeks using the analytic framework described in the primary outcome. Qualitative analysis will involve in-depth immersion in the transcripts and audio and the iterative creation and synthesis of analytical memos and codes to organize data toward thematic insights. The investigators will use a deductive-dominant approach wherein a subset of central codes are determined a priori to focus the analysis, with inductive emergence of additional codes during analysis. The investigators will use Nvivo to facilitate coding and analysis.

24 weeks
Change in Social Functioning
Aikaikkuna: 24 weeks

Convergent parallel mixed methods will be used to integrate the quantitative and qualitative data to capture the effect of the intervention on social functioning. The quantitative analysis will use the data from the Patient-Reported Outcomes Measurement Information System Social Function scales at 12 and 24 weeks using the analytic framework described in the primary outcome. Qualitative analysis will involve in-depth immersion in the transcripts and audio and the iterative creation and synthesis of analytical memos and codes to organize data toward thematic insights. The investigators will use a deductive-dominant approach wherein a subset of central codes are determined a priori to focus the analysis, with inductive emergence of additional codes during analysis. The investigators will use Nvivo to facilitate coding and analysis.

24 weeks
Change in Social Relationships
Aikaikkuna: 24 weeks

Convergent parallel mixed methods will be used to integrate the quantitative and qualitative data to capture the effect of the intervention on social relationships. The quantitative analysis will use the data from the Patient-Reported Outcomes Measurement Information System Social Relationships scales at 12 and 24 weeks using the analytic framework described in the primary outcome. Qualitative analysis will involve in-depth immersion in the transcripts and audio and the iterative creation and synthesis of analytical memos and codes to organize data toward thematic insights. The investigators will use a deductive-dominant approach wherein a subset of central codes are determined a priori to focus the analysis, with inductive emergence of additional codes during analysis. The investigators will use Nvivo to facilitate coding and analysis.

24 weeks
Change in Hair Cortisol
Aikaikkuna: 24 weeks

Evaluation of hair cortisol measured via collection of hair from the vertex of the scalp at baseline, 12, and 24 weeks. Changes in hair cortisol over time. which will be calculated using between-subject differences rather than within-subject differences, using a linear mixed-effects to evaluate changes from baseline in hair cortisol. Study wave will be a covariate in the models. The model will contain data from baseline (0 weeks), during-intervention (12 weeks), and post-intervention (24-weeks). These models will assess differences between waitlist control and intervention participants using an interaction between time and treatment indicator. Residual plots will examine model assumptions and model fit, with transformation of the outcomes (e.g. log, square-root, Box-Cox) used as needed to satisfy modelling assumptions (e.g. normality, constant variance) and achieve appropriate model fit.

24 weeks
Change in Conserved Transcriptional Response to Adversity
Aikaikkuna: 24 weeks

Evaluation of change in conserved transcriptional response to adversity (CTRA) will be measured via collection of blood and measuring leukocyte gene expression to determine the CTRA at baseline, 12 and 24 weeks. For the CTRA score, background subtraction and normalization of raw data, and operationalize inflammatory and antiviral gene activity will be performed. CTRA change will be calculated using between-subject differences using a linear mixed-effects to evaluate changes from baseline. Study wave will be a covariate in the models. The model will contain data from baseline (0 weeks), during-intervention (12 weeks), and post-intervention (24-weeks). These models will assess differences between waitlist control and intervention participants using an interaction between time and treatment indicator. Residual plots will examine model assumptions and model fit, with transformation of the outcomes used as needed to satisfy modelling assumptions and achieve appropriate model fit.

24 weeks
Change in Gut Microbiome Health
Aikaikkuna: 24 weeks

Gut microbiome health will be assessed at baseline, 12 and 24 weeks. Participants will collect stool into a collection tube. Full-length 16S Sequencing using PacBio SMRT-Cell platform will be used for microbiome community structure and alpha diversity analysis. The Shoreline Biome Complete StrainID Kit will be used for full length 16S library prep and sequencing will be performed at the Nationwide Children's Hospital Institute for Genomic Medicine Research. Sequences will be classified into Amplicon Sequence Variants (ASVs) using DADA2 and all statistical analysis will be performed using QIIME2, Songbird, and Qurro. Metagenomic sequencing will be performed by the OSUCCC Genomics Shared Resource using the Illumina NovaSeq SP Flow Cell from libraries produced with the KAPA Library System. Sequence filtering and scaffold assembly will be performed as (Co-I Proj 2 Gur) published, using MEGAHIT specifically. Differentially abundant genes will be identified with DESeq2, an R package.

24 weeks
Identify the organizational context and resources necessary to align, coordinate, and sustain academic-community-government partnerships focused on advancing cardiovascular health equity.
Aikaikkuna: 156 weeks

To determine the context and resources necessary to align, coordinate and sustain partnerships to advance health equity we will perform interviews with partners in the Black Impact intervention, take notes on partner meetings and review organizational documents. Through qualitative thematic analysis and structured content analysis of notes taken during on-site contextual inquiry and excerpts from key organizational documents we will develop themes. The themes, within and across data sources, will be summarized visually and narratively for presentation to organizational stakeholders during a series of co-creation sessions during which stakeholders will leverage insights from qualitative analyses to discuss and detail actions that can lead to greater alignment and coordination for current and future delivery of Black Impact and similar programs aimed at advancing cardiovascular health equity through academic-community-government partnerships.

156 weeks

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Yhteistyökumppanit

Tutkijat

  • Päätutkija: Joshua Joseph, MD, Ohio State University

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Yleiset julkaisut

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Torstai 24. elokuuta 2023

Ensisijainen valmistuminen (Todellinen)

Keskiviikko 28. lokakuuta 2026

Opintojen valmistuminen (Todellinen)

Keskiviikko 28. lokakuuta 2026

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Keskiviikko 13. syyskuuta 2023

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Tiistai 19. syyskuuta 2023

Ensimmäinen Lähetetty (Todellinen)

Tiistai 26. syyskuuta 2023

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Keskiviikko 4. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 2. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa